Pfizer said its Q1 2024 revenues were $14,879 million, down 20% from $18,486 million in the prior-year period, and down 19% excluding the impact of foreign exchange. The company cited the expected decline in Comirnaty and Paxlovid revenues as the main factor.

1. 01

   Pfizer said its Q1 2024 revenues were $14,879 million, down 20% from $18,486 million in the prior-year period, and down 19% excluding the impact of foreign exchange. The company cited the expected decline in Comirnaty and Paxlovid revenues as the main factor.

2. 02

   The company said Comirnaty revenues for Q1 2024 were $354 million, down 88% operationally, and Paxlovid revenues were $2.0 billion, down 50%. It said revenues excluding those two products were $12.5 billion, up 11% operationally.

3. 03

   Pfizer said Reported net income for Q1 2024 was $3,115 million (diluted EPS of $0.55), down 44% from $5,543 million (diluted EPS of $0.97) a year earlier. It said Adjusted diluted EPS was $0.82, down 33% from $1.23.

4. 04

   The company said it maintained its full-year 2024 revenue guidance of $58.5 to $61.5 billion and raised its Adjusted diluted EPS guidance to $2.15 to $2.35 from $2.05 to $2.25.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.